The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of MS-275 therein.

The present invention relates to use of gTso thal in manufacturing a medicament for the promotion of MS-275 to cross the blood-brain barrier (BBB), and belongs to the technical field of pharmaceutical preparation. Administration of the medicament manufactured by the use of the present invention in combination with MS-275 significantly increases MS-275 to cross the BBB into the brain tissue, and prominently promotes the accumulation of MS-275 therein.

This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer. Methods of inhibiting UDP-glucose dehydrogenase and improving the efficacy of additional prostate cancer therapies are also provided.

This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer. Methods of inhibiting UDP-glucose dehydrogenase and improving the efficacy of additional prostate cancer therapies are also provided.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

A method of treating an HIV infected human is carried out by injecting into the lymph nodes of the HIV infected human a composition comprising an amount of calcium bicarbonate dissolved or dispersed in a carrier fluid capable of being absorbed into the CD4+ cells (T cells) of the lymph nodes. This forms modified CD4+ cells that present antigens that can be then targeted and destroyed by the HIV infected human's natural immune system so that the CD4+ cells of the HIV infected are destroyed, thus preventing replication of the HIV virus. This may be used in conjunction with reducing the HIV in the blood by a liver treatment using a composition comprising HIV virus, blood lysine, and E. coli and/or dialysis using centrifuging and microfiltration.

A method of treating an HIV infected human is carried out by injecting into the lymph nodes of the HIV infected human a composition comprising an amount of calcium bicarbonate dissolved or dispersed in a carrier fluid capable of being absorbed into the CD4+ cells (T cells) of the lymph nodes. This forms modified CD4+ cells that present antigens that can be then targeted and destroyed by the HIV infected human's natural immune system so that the CD4+ cells of the HIV infected are destroyed, thus preventing replication of the HIV virus. This may be used in conjunction with reducing the HIV in the blood by a liver treatment using a composition comprising HIV virus, blood lysine, and E. coli and/or dialysis using centrifuging and microfiltration.

The present disclosure provides compounds useful as inhibitors of SARM1 NADase activity, compositions thereof, and methods of using the same. The present disclosure provides compounds useful for treating a neurodegenerative or neurological disease or disorder, compositions thereof, and methods of using the same.

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.

Provided herein is a method of treating, preventing, or alleviating one or more symptoms of cancer in a subject, comprising administering to the subject a therapeutically effective amount of: (i) ascorbic acid, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof; (ii) a quinone compound, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof; and (iii) a sodium glucose cotransporter inhibitor, or a single enantiomer, a mixture of enantiomers, or a mixture of diastereomers thereof; or a pharmaceutically acceptable salt, solvate, hydrate, or prodrug thereof.